Literature DB >> 1906538

Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats.

J Pratz1, S Mondot, F Montier, I Cavero.   

Abstract

In normo- or hyperglycemic (i.v. infusion of 50 mg/kg/min glucose over 30 min) pithed rats, diazoxide (1 mg/kg/min i.v. over 20 min) significantly reduced plasma insulin content. By contrast, cromakalim, nicorandil or RP 52891 even at doses 40-fold higher than those producing the same hypotensive effect as diazoxide in intact anesthetized normotensive rats, failed to change insulin plasma levels. Glibenclamide (0.01-0.3 mg/kg i.v.) pretreatment antagonized dose-dependently the hypoinsulinemic activity of diazoxide with an i.v. ED50 value of 49 +/- 1 microgram/kg. In pithed rats, diazoxide increased markedly plasma renin activity. This effect was almost inhibited completely by 20 mg/kg i.v., but not at all by a 1-mg/kg i.v. dose of glibenclamide. In pentobarbital-anesthetized rats, diazoxide (0.5-2 mg/kg/min i.v. over 20 min) produced decreases in mean carotid artery blood pressure which were antagonized dose-dependently by glibenclamide (5-20 mg/kg i.v.). This sulfonylurea (20 mg/kg i.v.) also prevented the hypotensive effects of several i.v. administered K+ channel activators (cromakalim, RP 52891 and nicorandil) but not those of numerous hypotensive agents such as acetylcholine, adenosine, bradykinin, clonidine, histamine, salbutamol, dihydralazine, papaverine, platelet aggregating factor, nitroglycerin, nitroprusside, nitrendipine and diltiazem. Although glibenclamide lowered plasma glucose levels, its blocking activity vis-à-vis the hypotension evoked by cromakalim was not affected when its hypoglycemic effects were reversed with an i.v. injection of glucose.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906538

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Cardioprotective effects of diazoxide on myocardial ischemia/reperfusion injury in rats.

Authors:  Kailun Zhang; Jing Zhao; Yunhai Yang; Zhiwei Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 2.  Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?

Authors:  P Pickkers; M Schachter; A D Hughes; M D Feher; P S Sever
Journal:  Diabetologia       Date:  1996-07       Impact factor: 10.122

3.  Binding of [3H]-P1075, an opener of ATP-sensitive K+ channels, to rat glomerular preparations.

Authors:  F Metzger; U Quast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 4.  ATP-sensitive K+ channels in the kidney.

Authors:  U Quast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

5.  Pharmacological evidence for a KATP channel in renin-secreting cells from rat kidney.

Authors:  U Russ; U Rauch; U Quast
Journal:  J Physiol       Date:  1999-06-15       Impact factor: 5.182

6.  Nicorandil safety in the long-term treatment of coronary heart disease.

Authors:  S Witchitz; J Y Darmon
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

7.  Evidence that the novel imidazoline compound FT005 is an alpha(2)-adrenoceptor agonist.

Authors:  Scott Slough; Gerald Guillaumet; Peter V Taberner
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 8.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

9.  Severity of diabetes governs vascular lipoprotein lipase by affecting enzyme dimerization and disassembly.

Authors:  Ying Wang; Prasanth Puthanveetil; Fang Wang; Min Suk Kim; Ashraf Abrahani; Brian Rodrigues
Journal:  Diabetes       Date:  2011-06-06       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.